410 related articles for article (PubMed ID: 11971122)
41. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
[TBL] [Abstract][Full Text] [Related]
42. [Emerging new therapies for relapsing remitting multiple sclerosis].
Anis S; Achiron A
Harefuah; 2014 Nov; 153(11):658-62, 687, 686. PubMed ID: 25563027
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
Dhib-Jalbut S
Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
[TBL] [Abstract][Full Text] [Related]
44. Interferon-beta1b for the treatment of multiple sclerosis.
Lam S; Wang S; Gottesman M
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1111-7. PubMed ID: 18680445
[TBL] [Abstract][Full Text] [Related]
45. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
; Rieckmann P
Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
[TBL] [Abstract][Full Text] [Related]
46. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
[TBL] [Abstract][Full Text] [Related]
47. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
48. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
49. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
50. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
51. The treatment of multiple sclerosis: current and future.
Polman CH; Hartung HP
Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119
[TBL] [Abstract][Full Text] [Related]
52. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Edan G; Comi G; Le Page E; Leray E; Rocca MA; Filippi M;
J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1344-50. PubMed ID: 21436229
[TBL] [Abstract][Full Text] [Related]
53. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Darbà J; Kaskens L; Sánchez-de la Rosa R
J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728
[TBL] [Abstract][Full Text] [Related]
55. Newer versus older treatments for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B; Cohen JA
Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
[TBL] [Abstract][Full Text] [Related]
56. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
Nuijten M; Mittendorf T
Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
[TBL] [Abstract][Full Text] [Related]
57. Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study.
Bendfeldt K; Egger H; Nichols TE; Loetscher P; Denier N; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Radue EW; Borgwardt SJ
Brain Res; 2010 Apr; 1325():174-82. PubMed ID: 20167205
[TBL] [Abstract][Full Text] [Related]
58. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
Murdoch D; Lyseng-Williamson KA
Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
[TBL] [Abstract][Full Text] [Related]
59. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
Teter B; Agashivala N; Kavak K; Chouhfeh L; Hashmonay R; Weinstock-Guttman B
Mult Scler; 2014 Jun; 20(7):830-6. PubMed ID: 24277325
[TBL] [Abstract][Full Text] [Related]
60. Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis.
Correia I; Marques IB; Sousa M; Batista S; Ferreira R; Nunes C; Macário C; Cunha L; Sousa L
J Clin Neurosci; 2016 Nov; 33():73-78. PubMed ID: 27542939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
